Citeline, Biomedtracker: see the drug development process th...
Catch up on any missed COVID-19 24 hour webinar sessions
PD-1/PD-L1 Inhibitors: The First Wave of Immuno-Oncology is a comprehensive look at the immuno-oncology landscape, and includes:
· An overview of the current immuno-oncology market
· Ongoing developments in the PD-1/PD-L1 therapy space
· Challenges with PD-1/PD-L1 inhibitor development and treatment
· An examination of:
o Non-small cell lung cancer (NSCLC)
o Bladder cancer
· A look at the future of immuno-oncology
Watch webinar recording here
Datamonitor Healthcare: data analysis and insight, Pink Shee...
By Tara Hansen
The FDA Oncology Center of Excellence’s ‘industry-wide evaluation’ of accelerated approvals has already led to withdrawals of four PD-1/PD-L1 inhibitor indications, with the Oncologic Drugs Advisory Committee set to review another six in late April. Over the next two years, an additional five indications may be up for review.
Datamonitor Healthcare: data analysis and insight
Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination.
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: